



Prodrome Sciences USA, LLC
Attention: Dayan B. Goodenowe, Ph.D., CEO
27518 Via Industria
Temecula, California 92590

Dear Dr. Goodenowe:

We acknowledge receipt of your correspondence dated January 29, 2026, in response to our letter of January 8, 2026, regarding observations made during our inspection conducted between December 17, 2024, and January 10, 2025.

We trust that the actions described in your letter will provide adequate measures to bring Prodrome Sciences USA, LLC into compliance with FDA regulations. Any written response and all correspondence will be included as a permanent part of your file.

Should you have any questions or concerns regarding this letter or the inspection, please write to me at the address given below.

Sincerely,

Digitally signed by BRITTANY L.
GARR-S
Date: 2026.03.19 11:03:07 -04'00'

Brittany L. Garr, MPH
Branch Chief
Compliance Enforcement Branch
Division of Enforcement and Postmarketing Safety
Office of Scientific Investigations
Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 51, Room 5352
10903 New Hampshire Avenue
Silver Spring, MD 20993

Cc: Nu Trelle Toodle
Senior Regulatory Compliance Manager
Compliance Insight, Inc.